WHO panel recommends Emergency Use Listing status for Covaxin

Hyderabad-based Bharat Biotech, which has developed Covaxin, submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine's Emergency Use Listing (EUL). Covaxin, demonstrated 77.8 per cent efficacy in its Phase 3 clinical trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3GOjyRG
via IFTTT